Literature DB >> 28382459

Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol.

Jinxia Lin1, Jian-Jiang Zhong2.   

Abstract

Our previous work showed that the biosynthesis of ansamitocin P-3 (AP-3), an anti-tumor agent, by Actinosynnema pretiosum was depressed by ammonium but enhanced by isobutanol in the medium. Here we show proteomics analyses on A. pretiosum in different fermentation conditions with and without ammonium or isobutanol using two-dimensional electrophoresis (2-DE), matrix-assisted laser desorption/ionization, and linear ion trap quadrupole mass spectrometry. Pairwise comparison of repetitive 2-DE maps was performed to find differentially expressed spots, and eight proteins were identified as functionally annotated ones. Among these proteins, D-3-phosphoglycerate dehydrogenase (PGDH) and glyceraldehyde 3-phosphate dehydrogenase showed statistically significant up-regulation in ammonium vs. basic or isobutanol medium, while fatty acid synthetase, histidine-tRNA ligase, transposase, molecular chaperone GroEL, SAM-dependent methyltransferase, and Crp/Fnr family transcriptional regulator were overexpressed in ammonium vs. basic medium. Based on the 2-DE data, exogenous L-serine which could inhibit the PGDH activity was added to the cultures with isobutanol, and a lower AP-3 production was confirmed under 2.5 mM serine addition (24 or 48 h).

Entities:  

Keywords:  Actinosynnema pretiosum; Ansamitocin P-3 production; Cellular physiology and metabolism; Proteomics; Secondary metabolite biosynthesis

Mesh:

Substances:

Year:  2017        PMID: 28382459     DOI: 10.1007/s00449-017-1763-5

Source DB:  PubMed          Journal:  Bioprocess Biosyst Eng        ISSN: 1615-7591            Impact factor:   3.210


  1 in total

1.  Improvement of Biosynthetic Ansamitocin P-3 Production Based on Oxygen-Vector Screening and Metabonomics Analysis.

Authors:  Xiaolin Zhu; Kaiyao Hou; Peiyang Zheng; Wenya Zhong; Jing Guo; Xiyue Zhao; Tingting Hong; Zhiqiang Cai
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-02       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.